{
  "claims": [
    {
      "claim_id": "C01",
      "claim": "Intratumoral mRNA vaccination broadens tumor antigen presentation, including MHC-I peptide display.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination",
          "line_ref": "L28"
        },
        {
          "quote": "Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape",
          "line_ref": "L29"
        }
      ],
      "caveat": "Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings."
    },
    {
      "claim_id": "C02",
      "claim": "mRNA vaccination induces a type I interferon-rich tumor state linked to sensitization.",
      "strength": "strong",
      "evidence": [
        {
          "quote": "Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors",
          "line_ref": "L31"
        },
        {
          "quote": "Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.",
          "line_ref": "L39"
        }
      ],
      "caveat": "Mouse model effects may not map one-to-one to all human tumors, limiting direct clinical extrapolation."
    },
    {
      "claim_id": "C03",
      "claim": "The combination rationale is supported by increased PD-L1 axis activity and improved mouse tumor control context.",
      "strength": "moderate",
      "evidence": [
        {
          "quote": "PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable",
          "line_ref": "L32"
        },
        {
          "quote": "Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.",
          "line_ref": "L46"
        }
      ],
      "caveat": "Vaccine-only and ICI-only arms showed limited durability/activity in some settings, so benefit depends on context and combination design."
    },
    {
      "claim_id": "C04",
      "claim": "Prior SARS-CoV-2 mRNA vaccination is associated with better survival among metastatic patients treated with ICI.",
      "strength": "tentative",
      "evidence": [
        {
          "quote": "Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment",
          "line_ref": "L30"
        },
        {
          "quote": "The human analysis is retrospective and non-randomized; residual confounding is likely.",
          "line_ref": "L49"
        }
      ],
      "caveat": "Because patient groups were non-randomized and clinically heterogeneous, this association should not be interpreted as definitive causality."
    }
  ]
}